# clinical - LLM run 003

- Script: `llm-test/clinical-llm.py`
- Exit code: `0`

## Terminal Output

```text
No cooldown configured for this backend.

======================================================================
ANSWER
======================================================================
Backend: openai
Model:   qwen2.5:7b
```python
context = """
CLINICAL TRIAL DOCUMENT:

[NOISE BLOCK 1 — random filler]
...

[TARGET FACT — buried segment]
PATIENT RECORD: Subject ID PT-2247
Site: Site 03 | Enroll date: 2024-09-02
Assigned drug: Compound VX-7 (high dose, 80mg)
Allergy flag: PCN-HIGH
Baseline creatinine: 1.34 mg/dL
Last visit: Week 16 | Status: Active
Treating physician: Dr. Anika Rao
Note: Subject PT-2247 is flagged for enhanced renal monitoring due to
creatinine trending above threshold at Week 12 visit (1.61 mg/dL).

[NOISE BLOCK 3 — random filler]
...

[NOISE BLOCK 7 — random filler]

[NOISE BLOCK 8 — similar entity decoy]
PATIENT RECORD: Subject ID PT-2247-SCREEN
Site: Site 03 | Screen date: 2024-08-28
Status: Screen pass — enrolled as PT-2247
Allergy flag recorded at screening: NONE
Baseline creatinine at screening: 1.29 mg/dL
Note: Pre-enrollment screening record only. Superseded by enrollment record.
"""

question = """
Q1 [Single-hop retrieval]:
What is the allergy flag currently recorded for subject PT-2247?
Answer with the exact flag value only.

Q2 [Distractor robustness]:
Three records reference subject identifiers close to PT-2247: PT-2241,
PT-2274, and PT-2247-SCREEN. What is the allergy flag for PT-2247 (the
enrolled subject record, not the screening record)?
Answer with the exact flag value only.

Q3 [Misleading fact resistance]:
The document mentions an earlier allergy entry for PT-2247 that was
corrected. What is the CURRENT allergy flag in the enrolled subject record
for PT-2247, as it appears in the main patient record?
Answer with the exact flag value only.

Q4 [Span extraction]:
Copy the exact sentence from the document that explains why PT-2247 is
flagged for enhanced renal monitoring.

Q5 [Multi-hop reasoning]:
Using only information present in this document:
- What drug and dose is PT-2247 receiving?
- What did the Phase I safety review committee recommend for subjects in
  that dose cohort?
Combine these two facts to explain what ongoing protocol action should
apply to PT-2247. Show your reasoning step by step.
"""

final_answer = """
Q1: PCN-HIGH
Q2: PCN-HIGH
Q3: PCN-HIGH
Q4: Subject PT-2247 is flagged for enhanced renal monitoring due to creatinine trending above threshold at Week 12 visit (1.61 mg/dL).
Q5: 
- From the document, PT-2247 receives Compound VX-7 in a high dose of 80mg.
- The Phase I safety review committee recommended continued monitoring of renal function markers for subjects in the high-dose arm.

Based on this information, enhanced renal monitoring is an ongoing protocol action that should apply to PT-2247 as they are receiving the higher dose and need closer attention to their renal functions.
"""

print(final_answer)
```

======================================================================
LATENCY BREAKDOWN
======================================================================
  Total wall time:    71.576s

======================================================================
TOKEN USAGE
======================================================================
qwen2.5:7b: input=1,645, output=743, calls=1
======================================================================
```
